source
- Roche reports up to 30% shrinkage of chronic MS lesions with fenebrutinib, eyes FDA approvalRoche has filed for FDA approval of its BTK inhibitor fenebrutinib for both relapsing and primary progressive multiple sclerosis, after the agency accepted the submission. At the MSToronto2026 mee…
- Biotech reverse mergers surge in 2026, reaching highest level since 2021 as PIPE financing spikesBiotech companies are using reverse mergers to re‑enter public markets at a rate not seen since 2021, according to a J.P. Morgan report released in October 2026. In the first nine months of 2026,…